B
Bicycle Therapeutics plc (BCYC)
NMS – Real Time Price. Currency in USD
4.72
+0.02 (0.43%)
At close: May 12, 2026, 4:00 PM EDT
4.85
+0.13 (2.69%)
After-hours: May 12, 2026, 6:50 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
4.72
+0.02 (0.43%)
At close: May 12, 2026, 4:00 PM EDT
4.85
+0.13 (2.69%)
After-hours: May 12, 2026, 6:50 PM EDT
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
| Name | Position |
|---|---|
| Dr. Christian Heinis | Scientific Founder |
| Dr. Jennifer Perry Pharm.D. | Chief Operating Officer |
| Dr. Kevin Lee M.B.A., Ph.D. | CEO & Executive Director |
| Dr. Michael Skynner B.sc. Ph.d., Ph.D. | Chief Scientific Officer |
| Dr. Phil Jeffrey | Senior VP of Pre-Clinical Development |
| Mr. Alistair Milnes | Chief Corporate Development Officer |
| Mr. Travis Thompson | Chief Financial Officer |
| Mr. Zafar Qadir | Chief Legal Officer & General Counsel |
| Ms. Stephanie Yao | Senior Vice President of Investor Relations and Corporate Communications |
| Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Ph.D. | Co-Founder & Independent Non-Executive Director |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | 8-K | tm2613019d1_8k.htm |
| 2026-04-22 | DEF 14A | bcyc-20260617xdef14a.htm |
| 2026-04-22 | ARS | tm262946d3_ars.pdf |
| 2026-04-20 | 8-K | tm2612166d1_8k.htm |
| 2026-04-03 | PRE 14A | bcyc-20260617xpre14a.htm |
| 2026-03-17 | S-8 | tm268887d2_s8.htm |
| 2026-02-03 | 8-K | tm264844d1_8k.htm |
| 2026-01-12 | 8-K | tm262874d1_8k.htm |
| 2025-10-30 | S-8 | tm2529594d1_s8.htm |
| 2025-10-30 | 10-Q | bcyc-20250930x10q.htm |